DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Ovarian
Cancer – Treatment Landscape & Competitive Analysis, 2017”
report to their offering.
Ovarian Cancer – Treatment Landscape & Competitive Analysis, 2017,
provides comprehensive insights about the treatment landscape across
this indication. This report also provides deep understanding of the
stages of ovarian cancer, the epidemiology, risk factors, diagnosis,
etc. A key objective of the report is to establish an understanding of
the treatment landscape and competitive analysis of ovarian cancer,
which mainly describes the treatment of ovarian cancer at different
stages. Ovarian cancer is the sudden growth of the cells in the ovary
and is a type of cancer that affects females only.
These days, companies are focusing on targeted therapy for cancer. Many
big pharmaceuticals companies are involved in ovarian cancer with their
pre-registration products. Cediranib of AstraZeneca and Paclitaxel of
Oasmia Pharmaceutical AB are ready to hit the market in the next few
years. All are in pre-registration stage.
Along with targeted therapy, this report also provides the landscape of
chemotherapy available for ovarian cancer. This report also covers the
comparison of targeted therapy and chemotherapy, which provides insights
for the marketed drugs. Analysis of the marketed drugs provides an
understanding of cost of treatment, therapeutic class, patent expiry and
sales data of the drugs. This recent report covers the treatment
landscape, which provides the treatment options by different stages of
ovarian cancer. Currently, the treatment is divided into Targeted
Therapy and Chemotherapy. There are two products under Targeted Therapy
and seven products under Chemotherapy.
Key Topics Covered:
Stages of Ovarian Cancer
- Treatment Options
- Ovarian Cancer Treatment Timeline
- Risk Factors
- Treatment Landscape
Treatment Options by Stage
- Stage IB
- Stage IC
- Stage IIA
Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV
- Ovarian Cancer: Marketed Products
- Targeted Therapy
Drug 1 – Product Profile
- Drug Description
- Advantages & Disadvantages
- Product Profile
- Historical Global Sales Data
- Drug 2 – Product Profile
- Advantages and Disadvantages
- Product Profile
Ovarian Cancer Marketed Drugs Analysis
- Marketed Drugs Analysis – By Type of Therapy
- Targeted Therapy vs. Chemotherapy
- Marketed Drugs Analysis – Patent Expiry and Drug Sales
Marketed Drugs Analysis – Cost of Treatment
- Current Unmet Needs for Ovarian Cancer Treatment
- Ovarian Cancer Phase III and Pre-Registration Drugs Analysis
Pipeline Product Analysis
– Bristol-Myers Squibb Company
– Nektar Therapeutics
– Bavarian Nordic A/S
– Amgen Inc.
– AstraZeneca Plc
– GlaxoSmithKline Plc
– Bioniche Life Sciences Inc.
– Genentech Inc.
– Novogen Limited
– Oncolytics Biotech Inc.
– OXiGENE Inc.
For more information about this report visit http://www.researchandmarkets.com/research/s3327j/ovarian_cancer.
Research and Markets
Laura Wood, Senior Manager
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716